SCHEMBL184580

SCHEMBL184580

O=C(O)Cc1csc(NC(=O)C(Oc2ccc(Cl)cc2F)c2ccc(S(=O)(=O)N3CCOCC3)cc2)n1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GCK P35557 6/20 0.58
ALDH1A1 P00352 1/20 0.49
CPT1A P50416 8/20 0.48
CPT1B Q92523 8/20 0.48
LMNA P02545 4/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
NOD2 Q9HC29 1/20 0.46
ATM Q13315 1/20 0.46
ADRB2 P07550 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185178 0.91 ALDH1A1 (0.62) GCKALDH1A1LMNATSHRHTT
SCHEMBL184805 0.87 GCK (0.77) GCKALDH1A1MAPTKDM4E
SCHEMBL2658888 0.86 GCK (0.56) GCKCPT1ACPT1B
SCHEMBL3772579 0.82 GCK (0.58) GCKALDH1A1HTTMAPTATM
SCHEMBL184997 0.82 PPARG (0.63) GCKALDH1A1TSHRSMN1; SMN2KDM4E
SCHEMBL184569 0.81 GCK (0.86) GCK
SCHEMBL184291 0.80 GCK (0.64) GCKALDH1A1LMNATSHRMAPT
SCHEMBL185444 0.79 GCK (0.89) GCKALDH1A1MAPTKDM4EGAA
SCHEMBL2657551 0.78 GCK (0.66) GCKHTT
SCHEMBL3805122 0.77 SMN1; SMN2 (0.51) GCKLMNAHTTMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US claimed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP claimed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US claimed
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA GCK 1/4885ALDH1A1 843/4885CPT1A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.